RxDoctor Payments DataLook up a doctor →

Zev Wainberg, MD

Hematology & Oncology · Santa Monica, CANPI 1104850932

Payments from drug & device makers

$19,263,451in general payments, 2019–2025

Across 1,251 payments — averaging $15,398 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$3.7M
  • Novartis$3.1M
  • Merck$1.5M
  • AstraZeneca$1.5M
  • Amgen$1.3M
  • Pfizer$1.3M
  • plus $6.8M from 42 others
$22,434in research payments, 2019–2025

Across 10 payments — averaging $2243.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$10K
  • Amgen$7K
  • Novartis$5K
  • Bristol Myers Squibb$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.104$3,712,698
Novartis87$3,136,312
Merck217$1,488,979
AstraZeneca48$1,456,222
Amgen46$1,324,763
Pfizer52$1,306,462
AbbVie74$1,010,901
Astrazeneca UK Limited20$941,398
E.r. Squibb & Sons, L.L.C.37$837,166
Eli Lilly50$817,360
Ipsen Bioscience Inc.46$620,686
Incyte Corporation121$586,485
Daiichi Sankyo Inc.44$529,182
Takeda Pharmaceuticals U.S.A., Inc.30$350,583
EMD Serono, Inc.37$184,234
Daiichi Sankyo Company LTD7$181,497
Seagen Inc.27$159,377
Array Biopharma Inc10$89,883
Gilead8$71,379
Bristol Myers Squibb7$69,685
Corcept Therapeutics10$50,838
Beone Medicines USA, Inc.12$50,806
Beigene, Ltd.3$44,302
Medivation LLC.56$40,217
Bayer21$35,448
Lilly USA, LLC11$25,885
Jazz Pharmaceuticals Inc.7$18,569
F. Hoffmann-la Roche AG9$18,030
Beone Medicines Ltd.2$12,921
Boehringer Ingelheim International GmbH5$11,840
Ipsen Biopharmaceuticals, Inc6$11,620
Mirati Therapeutics, Inc.2$9,900
Veloxis Pharmaceuticals, Inc.1$6,750
Janssen Scientific Affairs, LLC2$6,525
EMD Serono Research & Development Institute, Inc.3$6,210
Regeneron7$6,205
Astellas Pharma US Inc7$6,041
GSK4$4,874
Novocure Inc.1$4,125
Beigene USA, Inc.1$3,750
Merck Healthcare Kgaa1$3,195
Servier Affaires Medicales2$2,983
Eisai Inc.1$2,370
Boehringer Ingelheim1$2,220
Merck Kgaa1$1,380
Microvention, Inc.1$1,050
Genentech USA, Inc.1$125
Caris MPI, Inc.1$20

How this compares

$19,263,451 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024
$1,808,175
Medicare patients
387
Services billed
148,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Santa Monica

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →